# Gemcitabine in Ovarian Cancer

> **NCT00191334** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 50 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00191334
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2009-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191334, "Gemcitabine in Ovarian Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00191334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*